Broach Lifecare Hospital Limited recorded a significant expansion in its top line during the financial year 2025-26, with revenue from operations rising 88.55% to ₹599.47 lakh. Despite this robust growth, the company’s net profit contracted sharply to ₹8.68 lakh from ₹53.59 lakh in the previous year, primarily driven by elevated operating expenses.

The findings were disclosed during the proceedings of the company’s third Annual General Meeting (AGM), held on September 30, 2026, via video conferencing. The Board of Directors recommended no dividend for FY26, citing the need to conserve resources and strengthen the company’s financial position amidst ongoing growth and capacity requirements.

Financial performance and operational metrics

The hospital chain, operating under the brand Maple Hospitals, demonstrated substantial year-on-year growth in its core business activities. However, the bottom-line performance indicates pressure on margins as the company scaled its operations.

The divergence between the near-doubling of revenue and the steep decline in net profit highlights a period of intense investment or cost escalation relative to income generation. The statutory auditor, M/s. K. K. Haryani & Co., Chartered Accountants, did not raise any qualifications or adverse remarks regarding the financial statements for the year.

Governance and compliance updates

During the AGM, shareholders approved several key resolutions through remote e-voting facilitated by National Securities Depository Limited (NSDL). The agenda included the adoption of audited financial statements and the re-appointment of Managing Director Jaykumar Narendra Vyas.

Key resolutions passed:

• Adoption of audited financial statements for FY26.
• Re-appointment of Jaykumar Narendra Vyas as Managing Director.
• Appointment of M/s. Rahul S. Mithaiwala & Co. as Secretarial Auditor for five years (FY27-FY31).

The Secretarial Auditor noted two compliance lapses: a delay in filing the Reconciliation of Share Capital Audit Report for the quarter ended December 2025, and non-filing of Form MGT-14 for the appointment of certain auditors. The company stated it has strengthened internal monitoring mechanisms to prevent recurrence.

What the numbers show

A critical observation from the FY26 results is the inverse relationship between volume growth and profitability. While revenue nearly doubled, net profit fell by over 80%, suggesting that incremental costs associated with scaling operations significantly outpaced revenue gains. This pattern often indicates heavy upfront capital expenditure or operational inefficiencies during a rapid expansion phase, which may impact short-term shareholder returns given the decision to withhold dividends.

Broach Lifecare Hospital accepted the resignation of Ms. Urvi Mrunal Hindia as Chief Financial Officer, effective August 31, 2026. The company disclosed the departure to BSE Limited on September 11, 2026, citing personal reasons for her exit.

The firm responded to a query from the exchange regarding its initial corporate announcement dated August 25, 2026. While the resignation event was communicated on time, the actual resignation letter was inadvertently not attached to that disclosure.

Regulatory Compliance Details

Broach Lifecare clarified that there was no delay in disclosing the resignation itself, as the exchange was notified prior to the effective date. However, the supporting document was not submitted within the mandated seven days from the effective date of resignation.

The company assured regulators that internal checks have been strengthened to prevent such omissions in the future. A copy of the resignation letter and disclosures pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, were attached to the reply.

Key Disclosures

Ms. Hindia tendered her resignation on August 24, 2026. The Managing Director, Jaykumar Narendra Vyas, signed the communication to the stock exchange, confirming the cessation of her duties.